


a) Summary of pre-pandemic controls and vaccinated cohorts

Variables	Pre-pandemic Controls	Comirnaty / BNT162b2 (Pfizer-BioNtech) vaccinees		ChAdOx1 nCoV-19 (AstraZeneca) vaccinees
	Pre-pandemic (n=20)	Vaccinated only (n=20)	COVID-19 Recovered (Convalescent, vaccinated) (n=10)	Vaccinated only (n=17)
Age, mean (range), years	30.5 (21 – 60)	34.6 (26 – 58)	49.5 (24 – 65)	46.5 (23 – 69)
Gender				
Female (%)	16 (80.0%)	13 (65.0%)	6 (60.0%)	10 (58.8)
Male (%)	4 (20.0%)	7 (35.0%)	4 (40.0%)	7 (41.2)
Time from symptom onset till sample collection, mean (range), days			478.1 (412 – 534)	
Vaccination				
Time after 1 st shot till sample collection, mean (range), days		9.1 (6 – 12)	12.5 (7 – 18)	13.4 (7 – 22)
Time between 1 st and 2 nd shot, mean (range), days		24.0 (21 – 33)	28.0 (21 – 48)	83 (70 – 92)
Time after 2 nd shot till sample collection, mean (range), days		14.1 (12 – 22)	20.1 (10 – 34)	13.4 (7 – 22)
Time between 2 nd shot and 5 months sample collection, mean (range), days		218.8 (188 – 226)		149.6 (101 – 184)
Time after 3 rd shot till sample collection, mean (range), days		12.4 (10 – 15)		20.1 (10 – 31)


b) Summary of breakthrough cohorts

Variables	Delta breakthroughs	Omicron BA.2 breakthroughs
	(n=8)	(n=10)
Age, mean (range), years	34.6 (19 – 58)	54.3 (40 – 66)
Gender		
Female (%)	5 (62.5%)	5 (50.0%)
Male (%)	3 (37.5%)	5 (50.0%)
Vaccination doses prior to breakthrough infection (%)	2 (100.0%)	3 (100.0%)
Time from last vaccination till breakthrough infection, mean (range), months	3.3 (0.3 – 5.3)	3.2 (1.6 – 5.3)


c) Sampling timepoints for breakthrough infections




d) Schematic of SARS-CoV-2 spike protein




a)




b)




Saliva antibody comparisons after two antigen exposures




Saliva antibody comparisons after three antigen exposures




Tear antibody comparisons after three antigen exposure




Saliva and tear IgA in COVID-19 recovered individuals following BNT162b2 vaccination



Comparisons of saliva anti-Spike 2 responses after mRNA boosters in vaccinated only cohort





Plasma antibody signatures following BNT162b2 vaccination




Plasma antibody comparisons after two antigen exposures


Plasma antibody comparisons after three antigen exposures




Comparisons of plasma anti-Spike 2 responses after mRNA boosters in vaccinated only cohort




ChAdOx1 nCoV-19 vaccinated cohort timepoints



Saliva and plasma antibody signatures following ChAdOx1 nCoV-19 vaccination





Breakthrough infections, viral load kinetics



Saliva SARS-CoV-2 VoC antibody signatures following breakthrough infections

% ACE2 Inhibition (≤5 days vs 2 weeks post-onset)



FcγR3a Responses (≤5 days vs 2 weeks post-onset)




Plasma SARS-CoV-2 VoC antibody signatures following breakthrough infections

% ACE2 Inhibition (≤5 days vs 2 weeks)



FcγR3a Responses (≤5 days vs 2 weeks)



Breakthrough infections, comparison of antibody responses vs viral load



Saliva antibody responses over time, breakthrough infections



Plasma antibody responses over time, breakthrough infections

